Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1541 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

    Article Cited by others

ORIGINAL ARTICLE

Spironolactone in chronic hemodialysis patients improves cardiac function

Taheri Shahram, Mortazavi Mojhgan, Shahidi Shahrzad, Pourmoghadas Ali, Garakyaraghi Mohammad, Seirafian Shiva, Eshaghian Afrooz, Ghassami Maryam

Year : 2009| Volume: 20| Issue : 3 | Page no: 392-397

   This article has been cited by
 
1 Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients
Flevari, P. and Kalogeropoulou, S. and Drakou, A. and Leftheriotis, D. and Panou, F. and Lekakis, J. and Kremastinos, D. and Vlahakos, D.V.
Journal of Hypertension. 2013; 31(6): 1239-1244
[Pubmed]  [Google Scholar]
2 Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients
Drechsler, C. and Ritz, E. and Tomaschitz, A. and Pilz, S. and Schönfeld, S. and Blouin, K. and Bidlingmaier, M. and Hammer, F. and Krane, V. and März, W. and Allolio, B. and Fassnacht, M. and Wanner, C.
European Heart Journal. 2013; 34(8): 578-585b
[Pubmed]  [Google Scholar]
3 Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: A meta-analysis of randomised controlled trials
Phelan, D. and Thavendiranathan, P. and Collier, P. and Marwick, T.H.
Heart. 2012; 98(23): 1693-1700
[Pubmed]  [Google Scholar]
4 Mineralocorticoid receptor-associated hypertension and target organ damage: Clinical relevance for resistant hypertension in end stage renal disease
Rekhtman, Y. and Bomback, A.S.
Current Hypertension Reviews. 2012; 8(4): 267-275
[Pubmed]  [Google Scholar]
5 Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis [Les antagonistes du récepteur minéralocorticoïde sont-ils sécuritaires chez les patients hémodialysés?]
Baker, W.L. and White, W.B.
Annals of Pharmacotherapy. 2012; 46(6): 889-894
[Pubmed]  [Google Scholar]
6 Mineralocorticoid receptor blockade in chronic kidney disease
Bomback, A.S. and Klemmer, P.J.
Blood Purification. 2012; 33(1-3): 119-124
[Pubmed]  [Google Scholar]
7 Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: Current concepts and emerging treatment paradigms
Shavit, L. and Lifschitz, M.D. and Epstein, M.
Kidney International. 2012; 81(10): 955-968
[Pubmed]  [Google Scholar]
8 Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - A pilot study
Shavit, L. and Neykin, D. and Lifschitz, M. and Slotki, I.
Clinical Nephrology. 2011; 76(5): 388-395
[Pubmed]  [Google Scholar]
9 The 2011 Canadian cardiovascular society heart failure management guidelines update: Focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care
McKelvie, R.S. and Moe, G.W. and Cheung, A. and Costigan, J. and Ducharme, A. and Estrella-Holder, E. and Ezekowitz, J.A. and Floras, J. and Giannetti, N. and Grzeslo, A. and Harkness, K. and Heckman, G.A. and Howlett, J.G. and Kouz, S. and Leblanc, K. and Mann, E. and OMeara, E. and Rajda, M. and Rao, V. and Simon, J. and Swiggum, E. and Zieroth, S. and Arnold, J.M.O. and Ashton, T. and DAstous, M. and Dorian, P. and Haddad, H. and Isaac, D.L. and Leblanc, M.-H. and Liu, P. and Sussex, B. and Ross, H.J.
Canadian Journal of Cardiology. 2011; 27(3): 319-338
[Pubmed]  [Google Scholar]
10 Should all hypertensive dialysis patients receive a blocker of the renin-angiotensin system?
Sinha, A.D. and Agarwal, R.
Current Hypertension Reports. 2010; 12(5): 356-363
[Pubmed]  [Google Scholar]
11 Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: Is it safe?
Chua, D. and Lo, A. and Lo, C.
Clinical Cardiology. 2010; 33(10): 604-608
[Pubmed]  [Google Scholar]
12 Mineralocorticoid receptor blockers and chronic kidney disease
Jain, G. and Campbell, R.C. and Warnock, D.G.
Clinical Journal of the American Society of Nephrology. 2009; 4(10): 1685-1691
[Pubmed]  [Google Scholar]

 

Read this article